Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma

Leukemia

Volumn 15, Issue 4, 2001, Pages 635-641

  Mitterbauer, M ^a   Neumeister, P ^b   Kalhs, P ^a   Brugger, S ^a   Fischer, G ^c   Dieckmann, K ^a   Hoecker, P ^c   Hinterberger, W ^a   Linkesch, W ^b   Simonitsch, I ^a   Jaeger, U ^a   Lechner, K ^a   Mannhalter, C ^a   Mitterbauer, G ^a   Greinix, H T ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

AlloSCT; BCL2 IgH; Immunoglobulin rearrangement; Non Hodgkin's lymphoma; Polymerase chain reaction

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN BCL 2;

ADULT; ALLOGRAFT; ARTICLE; AUSTRIA; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; ERADICATION THERAPY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE BIOPSY; MALE; MINIMAL RESIDUAL DISEASE; MONITORING; MORTALITY; NONHODGKIN LYMPHOMA; PATIENT REFERRAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; STEM CELL TRANSPLANTATION; SURVIVAL; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

EID: 0035074832     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402053     Document Type: Article

References (49)

1. Non-Hodgkin's lymphoma time trends: United States and international data
2. Recent advances in the molecular pathogenesis of lymphomas
3. International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma
4. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
5. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
6. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma
7. Treatment of patients with relapsed and resistent non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation
8. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission
9. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma
10. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment
11. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma
12. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma
13. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation
14. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation
15. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European bone marrow transplant group registry data
16. Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma
17. Allogeneic transplantation for low-grade lymphoma: Long-term follow-up
18. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: Clinical and molecular follow up
19. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non Hodgkin's lymphoma
20. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphatic leukemia
21. Combined polymerase chain reaction approach for clonality detection in lymphoid neoplasms
22. Distinctive chromosomal abnormalities in histological subtypes of non-Hodgkin's lymphoma
23. Leukemia-free survival and mortality in patients with refractory or relapsed acute leukemia given marrow transplants from sibling and unrelated donors
24. Bone marrow transplantation
25. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia
26. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: Association between low cyclosporine concentration and risk of acute graft-versus-host disease
27. IBMTR severity index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade
28. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression
29. Prevention and treatment of cytomegalo-virus infection and disease after bone marrow transplantation in the 1990s
30. Detection of engraftment and mixed chimerism following bone marrow transplantation using PCR amplification of a highly variable region-variable number of tandem repeats (VNTR) in the von Willebrand factor gene
31. Family studies and prenatal diagnosis in severe von Willebrands disease by polymerase chain reaction amplification of variable number of tandem repeat region of the von Willebrand factor gene
32. A tetranucleotide repeat for the F13B locus
33. Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction
34. Nonparametric estimation from incomplete observations
35. Lack of t(14;18) polymerase chain reaction-positive cells in highly purified CD34+ cells and their CD19 subsets in patients with follicular lymphoma
36. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoblastic lymphoma): A series of 73 patients from the SFGM data base
37. Allogeneic bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma
38. Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin's lymphoma
39. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma
40. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies
41. Allogeneic hematopoietic tranplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft versus-malignancy
42. Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect
43. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up
44. Eradication of polymerase chain reaction immunoglobulin rearrangement in non-Hodgkin's lymphoma is associated with decreased relapse after autologous bone marrow transplantation
45. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
46. Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma
47. Allogeneic peripheral blood stem cell transplantation for the treatment of refractory follicular lymphoma